OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more
OUTLOOK THERAPEUTICS INC (OTLK) - Total Liabilities
Latest total liabilities as of September 2025: $50.77 Trillion USD
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has total liabilities worth $50.77 Trillion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OUTLOOK THERAPEUTICS INC - Total Liabilities Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OUTLOOK THERAPEUTICS INC Competitors by Total Liabilities
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
8AV0
F:8AV0
|
Germany | €5.66 Million |
|
Graphex Group Limited
NYSE MKT:GRFX
|
USA | $510.07 Million |
|
Security Bancorp Inc
PINK:SCYT
|
USA | $345.41 Million |
|
Fast Food Indonesia Tbk
JK:FAST
|
Indonesia | Rp4.12 Trillion |
|
American Realty Investors Inc
NYSE:ARL
|
USA | $287.64 Million |
|
Neo Cremar Co. Ltd
KQ:311390
|
Korea | ₩40.82 Billion |
|
Arianne Phosphate Inc
OTCQX:DRRSF
|
USA | $46.27 Million |
|
Vortex Consolidated Bhd
KLSE:0060
|
Malaysia | RM63.53 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down OUTLOOK THERAPEUTICS INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1577369.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OUTLOOK THERAPEUTICS INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $50.77 Trillion | +49825230.14% |
| 2024-09-30 | $101.90 Million | +118.02% |
| 2023-09-30 | $46.74 Million | +136.16% |
| 2022-09-30 | $19.79 Million | +8.72% |
| 2021-09-30 | $18.20 Million | +7.67% |
| 2020-09-30 | $16.91 Million | -39.41% |
| 2019-09-30 | $27.90 Million | -35.25% |
| 2018-09-30 | $43.09 Million | -16.26% |
| 2017-09-30 | $51.46 Million | +78.03% |
| 2016-09-30 | $28.91 Million | -17.77% |
| 2015-09-30 | $35.15 Million | -45.30% |
| 2014-09-30 | $64.26 Million | -- |